Aclaris Therapeutics, Inc. Cash and Restricted Cash
Aclaris Therapeutics, Inc. (ACRS) had Cash and Restricted Cash of $19.17 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $19.17M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $28.66M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $19.96M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $25.26M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $19.17M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $28.66M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $19.96M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $25.26M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $25.40M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $30.36M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $24.57M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $47.65M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $22.83M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $35.84M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $39.88M 10-K · filed 2026-02-26 |
| 2023-09-30 | $39.04M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $31.15M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $44.72M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $45.28M 10-K · filed 2025-02-27 |
| 2022-09-30 | $61.65M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $68.26M 10-Q · filed 2023-08-07 |
| 2022-03-31 | $36.34M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $27.35M 10-K · filed 2024-02-27 |
| 2021-09-30 | $53.60M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $113.45M 10-Q · filed 2022-08-03 |
| 2021-03-31 | $35.27M 10-Q · filed 2022-05-10 |
| 2020-12-31 | $22.06M 10-K · filed 2024-02-27 |
| 2020-09-30 | $25.40M 10-Q · filed 2021-11-02 |
| 2020-06-30 | $32.59M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $53.99M 10-Q · filed 2021-05-07 |
| 2019-12-31 | $35.94M 10-K · filed 2023-02-23 |
| 2019-09-30 | $29.90M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $31.65M 10-Q · filed 2020-08-07 |
| 2019-03-31 | $34.20M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $57.02M 10-K · filed 2022-02-24 |
| 2018-09-30 | $26.59M 10-Q · filed 2019-11-07 |
| 2018-06-30 | $46.03M 10-Q · filed 2019-08-08 |
| 2018-03-31 | $54.88M 10-Q · filed 2019-05-08 |
| 2017-12-31 | $20.20M 10-K · filed 2021-02-25 |
| 2017-09-30 | $60.05M 10-Q · filed 2018-11-06 |
| 2017-06-30 | $32.71M 10-Q · filed 2018-08-03 |
| 2016-12-31 | $30.17M 10-K · filed 2020-02-25 |
| 2015-12-31 | $9.85M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |